Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference


LOS ANGELES, Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston. Dave Lennon, Ph.D., President and CEO, will present a company overview on Monday, March 4, 2024, from 2:10 PM ? 2:40 PM ET.

The presentation will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for cancers to bring transformational therapies to cancer patients with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
[email protected]

(PRNewsfoto/Aadi Bioscience)

 

SOURCE Aadi Bioscience


These press releases may also interest you

at 15:25
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

at 15:02
U.S.-based Iozera announces MOU with Government of Morocco for Launch of Eco-Friendly AI Data Center in Morocco
U.S.-based tech startup Iozera, in collaboration with the Government of Morocco, announces an initiative set to transform the AI industry. Iozera has announced the signing of a Memorandum of Understanding (MOU) for the establishment of a pioneering...

at 13:12
Flash News: OK Wallet Now Integrated with JUICE, a Permissionless DeFi Protocol Built on the Blast Ecosystem's Layer 2 Infrastructure
OKX, a leading Web3 technology company, has issued updates for May 3, 2024. OKX today announced that its Web3 Wallet is now...

at 11:55
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

at 11:49
Quick understanding of JA Solar's 2023 annual report
With a remarkable achievement of 81.556 billion yuan in operating revenue, marking an 11.74% increase from the previous year, and a net profit attributable to shareholders of 7.039 billion yuan, soaring by 27.21%, JA Solar hit historic highs in both...

at 10:00
Sogolytics Highlights AI-Powered Updates at UNLEASH America
Leading research and experience management firm Sogolytics will showcase innovations in HR and employee experience at UNLEASH America next week. "With such a rapid evolution in the world of HR tech, we're seeing some major changes in how employers...

More news about Science and technology...


News published on and distributed by: